Lantern Pharma is trading 10.43% up at $2.75 in after-hours trading, with no verified company-specific announcement emerging on August 19, 2026.
- Latest reported earnings, released August 14, showed improved operating efficiency and clinical progress, alongside a wider net loss and funding concerns.
- The move is not aligned with modest broader-market gains; no clear catalyst explains the surge, warranting a re-check for delayed news.